Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Immunocore stock | $34.28

Learn how to easily invest in Immunocore stock.

Immunocore Holdings plc
NASDAQ: IMCR - USD
BIOTECHNOLOGY
$34.28
+ $1.68 ( + 5.15%)

Immunocore Holdings plc is a biotechnology business based in the US. Immunocore shares (IMCR) are listed on the NASDAQ and all prices are listed in US Dollars. Immunocore employs 291 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Immunocore

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMCR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Immunocore stock price (NASDAQ: IMCR)

Use our graph to track the performance of IMCR stocks over time.

Immunocore shares at a glance

Information last updated 2021-09-18.
Latest market close$34.28
52-week range$26.00 - $61.99
50-day moving average $31.72
200-day moving average $36.96
Wall St. target price$52.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.04

Buy Immunocore shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Webull
Stocks, Options, ETFs
$0
0%
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Immunocore stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immunocore price performance over time

Historical closes compared with the close of $34.28 from 2021-09-17

1 week (2021-09-10) 7.02%
1 month (2021-08-18) 14.65%
3 months (2021-06-18) -16.33%
6 months (2021-03-19) -21.07%
1 year (2020-09-15) N/A
2 years (2019-09-15) N/A
3 years (2018-09-15) N/A
5 years (2016-09-15) N/A

Immunocore financials

Revenue TTM $28.1 million
Gross profit TTM $30.1 million
Return on assets TTM -27.45%
Return on equity TTM -78.54%
Profit margin 0%
Book value $5.07
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting Immunocore shares

There are currently 167,691 Immunocore shares held short by investors – that's known as Immunocore's "short interest". This figure is 53.9% down from 363,535 last month.

There are a few different ways that this level of interest in shorting Immunocore shares can be evaluated.

Immunocore's "short interest ratio" (SIR)

Immunocore's "short interest ratio" (SIR) is the quantity of Immunocore shares currently shorted divided by the average quantity of Immunocore shares traded daily (recently around 98064.912280702). Immunocore's SIR currently stands at 1.71. In other words for every 100,000 Immunocore shares traded daily on the market, roughly 1710 shares are currently held short.

To gain some more context, you can compare Immunocore's short interest ratio against those of similar companies.

However Immunocore's short interest can also be evaluated against the total number of Immunocore shares, or, against the total number of tradable Immunocore shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunocore's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Immunocore shares in existence, roughly 0 shares are currently held short) or 0.0068% of the tradable shares (for every 100,000 tradable Immunocore shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunocore.

Find out more about how you can short Immunocore stock.

Immunocore share dividends

We're not expecting Immunocore to pay a dividend over the next 12 months.

Immunocore overview

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom. .

Frequently asked questions

What percentage of Immunocore is owned by insiders or institutions?
Currently 22.092% of Immunocore shares are held by insiders and 35.329% by institutions.
How many people work for Immunocore?
Latest data suggests 291 work at Immunocore.
When does the fiscal year end for Immunocore?
Immunocore's fiscal year ends in December.
Where is Immunocore based?
Immunocore's address is: 92 Park Drive, Abingdon, United Kingdom, OX14 4RY
What is Immunocore's ISIN number?
Immunocore's international securities identification number is: US45258D1054

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site